Hint mode is switched on Switch off

MapLight Therapeutics, ordinary share
MPLT, US56565P1030

Add a stock to WL
Choose all Reset all
MapLight Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial ...
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis. The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    MapLight Therapeutics, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    MPLT
  • Placement
    27.10.2025
  • Lock up period
    180
  • Number of papers
    14,750,000
  • Volume of raised funds
    250.75 mln USD
  • Placement share
    35.6%
  • Final placement price
    17 USD
  • Price change since placement date
    -100%
  • By capitalization
    704.29 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
III q eng
Show all Hide

Related Stock indices

Indicators

News

23/06/2026 MapLight Therapeutics: Submission Of Matters To A Vote Of Security Holders
22/06/2026 MapLight Therapeutics: Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
23/04/2026 MapLight Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
04/12/2025 MapLight Therapeutics: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
26/10/2025 MapLight Therapeutics: Unregistered Sales Of Equity Securities, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Other Events, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.